Mutant p53 gene linked with colorectal cancer tumour growth

By genetically manipulating and removing the most common mutant form of the p53 gene that promotes colorectal cancer in humans, an international team of scientists has demonstrated that this therapy reduces tumour growth and tissue invasion. The research was led by Dr Ute Moll, Professor and cancer biologist in the Department of Pathology at Stony Brook University School of Medicine, the findings published in Cancer Cell.

Disrupted nitrogen metabolism linked to development of colon cancer

Researchers at the Weizmann Institute of Science, in collaboration with colleagues from the National Cancer Institute and elsewhere, have shown that in many cancers a patient's nitrogen metabolism is altered, producing detectable changes in the body fluids and contributing to the emergence of new mutations in cancerous tissue. The study, ‘Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures,’ published in Cell, may in the future facilitate early detection of cancer and help predict the success of immunotherapy.

Brassica genus vegetables prevent colon cancer in mice

Chemicals produced by vegetables such as kale, cabbage and broccoli could help to maintain a healthy gut and prevent colon cancer, according to a study from the Francis Crick Institute shows. The research, ‘The Environmental Sensor AHR Protects from Inflammatory Damage by Maintaining Intestinal Stem Cell Homeostasis and Barrier Integrity’, published in Immunity, shows that mice fed on a diet rich in indole-3-carbinol, which is produced when we digest vegetables from the Brassica genus, were protected from gut inflammation and colon cancer.

Trial to evaluate virotherapy and immunotherapy combination for ovarian and colorectal cancers

Ludwig Cancer Research and the Cancer Research Institute (CRI) have announced the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumour virotherapy, with the checkpoint blockade antibody IMFINZI (durvalumab) for advanced ovarian and colorectal cancers.

Experimental compound interferes with the first steps of the RAS/MAPK pathway slowing colon cancer

As many as 50 percent of human cancer cases, across a wide variety of tissues, involve defects in a common cellular growth signalling pathway. These defects have so far defied most attempts to develop targeted therapies, leading some in the field to conclude that they may be ‘undruggable’. Now researchers at UC San Francisco and Redwood City-based Revolution Medicines, have identified a new strategy for potentially treating a subset of such intractable cancers by decoupling the entire RAS/MAP Kinase (MAPK) signalling pathway from external growth signals.